Prescription Drug Abuse and Canada’s Lagging Regulatory Framework Craig Landau and Doug Sommerville

In Budget 2016, the Trudeau government was true to its campaign word. It will negotiate a new Health Accord with the provinces and territories and invest in mental health, palliative care, vaccination uptake and population health interventions with First Nations communities. However, notably absent was mention of Canada’s National AntiDrug Strategy which includes tactics to address prescription opioid misuse, abuse and diversion along with the broader utilization of abuse-deterrent/tamper-resistant formulations by pharmaceutical manufacturers. The Canadian heads of two leading innovative and generic pharma companies are of one mind on this issue.

Read the entire article in PDF format at PolicyMagazine.ca